UNSPSC 51401520: Elfazepam

This classification denotes an anxiolytic with the molecular formula C19H18ClFN2O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RM53R5R2BL, chemically known as 7-chloro-1-(2-(ethylsulfonyl)ethyl)-5-(o-fluorophenyl)-1,3-dihydro-2h-1,4-benzodiazepin-2-one but generally known as elfazepam, which bears US NIH Compound Identifier 65445. European Medicines Agency schedules Elfazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06483MIG.

UNSPSC 51401520 Elfazepam is a Commodity code that in practice captures state and local procurement of pharmaceutical products and drug-related health-support systems. Recent solicitations show state and local agencies buying naloxone (an opioid-overdose reversal medication), safe drug deactivation systems, and generic multi-source pharmaceuticals and over-the-counter products through competitive bidding, cooperative purchasing, and information-gathering phases. The issuing bodies span county health departments, state human services commissions, and multistate cooperative purchasing alliances; Seminole County, Florida and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) appear as active recent buyers.

Activity concentrates in Florida and the Upper Midwest (Minnesota, with Oregon participation through MMCAP), with Texas HHS initiating exploratory procurement in the prescription-program space. Representative recent solicitations include Seminole County's IFB60459723LAS (posted June 30, 2026, due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually for quarterly delivery to the county's community health building; the Texas Health and Human Services Commission's RFI HHS0017013 (posted April 3, 2026) soliciting vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program; and MMCAP's S1070000015802 RFP (posted January 20, 2026, due March 26, 2026) establishing multiple contracts for generic pharmaceuticals and OTC products across state and local government facilities, with awarded vendors effective July 1, 2026, and performance penalties ranging from $200 to $1,500 per violation. The Seminole County contract carries a two-year initial term with one-year renewal option; MMCAP contracts run two years for new responders with optional extensions, incumbent responders aligned through June 30, 2028.